C-BAMWViCardia Therapeutics
mitochondrial dysfunction, AMPK activation, infusion therapy
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BAMW
C-BAMWC-BAMWmitochondrial dysfunction, AMPK activation, infusion therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Ucardia Announces Acquisition of PHAS3; Launches Cardiologist Practice Remote Patient Monitoring Offering | DAIC "" Skip to main content X Search this site Eyebrow Menu About About Advertise Archive Contact Us DAIC Awards Subscribe to newsletters Blogs Blogs Blog Series Buyer's Guide Calendar Case Studies Comparison Charts Videos Videos Innovative Hospital Videos Webinars Search this site Sign In New User? Register Here Cath Lab Angiography systems Balloon catheters FFR Technologies Hemostasis management Hemodynamic Support Hybrid OR Innovative Hospitals Baylor Scott and White Heart Hospi
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
News | Hatteras Venture Partners Healthcare Insights investor login contact team dedicated funds news portfolio Discover the Latest browse by categories hatteras venture partner news Portfolio Company News Hatteras blogs browse by categories Search for: Hatteras Venture Partners News HistoSonics Announces Financing with Participation from Yosemite Among Other Strategic Investors June 22, 2026 Values Company at $3.75 Billion and Funds Development of Additional Clinical Applications MINNEAPOLIS–(BUSINESS WIRE)–HistoSonics, the developer of the Edison® Histotripsy System and nov … recent Hatteras Venture Partners Honors HistoSonics with the Charles A. Sanders Award for Entrepreneurial Excellence November 6, 2025 Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds August 13, 2025 A top Research Triangle based venture capital investor shares an overview of the life sciences ecosystem in North Carolina. May 22, 2024 They’re Back – Will We See the M&A Boon? Hatteras White Paper on Biotech M&A May 11, … 15, 2019 CEO Roundtable on Cancer Presents Dr. Charles A. Sanders Life Sciences Award to Jean Becker, Ken Lee and Phil Porter November 19, 2018 Sir Andrew Witty Joins Hatteras Venture Partners September 19, 2017 Sept. 19, 2017 — DURHAM, NC — Hatteras Venture Partners today announced it has named Sir Andrew Witty a Venture Partner. Mr. Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the ever-changing global health care industr … nt Hatteras Venture Partners Announces Launch of the Venture Capital Multiplier Fund February 28, 2017 Hatteras Venture Partners Announces the Final Closing of Hatteras Venture Partners V, LP January 5, 2017 Hatteras Venture Partners Earns CEO Cancer Gold Standard Accreditation April 25, 2016 TBJ names 2016 Women in Business Lifetime Achievement Award winner March 7, 2016 Each year as a part of its annual Women In Business Awards, Triangle Business Journal selects a female ex … dedication to the community’s greater good. We call it the Lifetime Achievement Award. view the most recent Carolina Research Ventures Selects Hatteras as Manager of Investments March 2, 2016 Hatteras Venture Partners Announces First Closing of HVP V August 25, 2015 UNC Kenan-Flagler Distinguished Alumni Award November 21, 2013 “IMPACT: The Art a
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
ViCardia Therapeutics, Inc. - BIO Investor Forum | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membershi
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Imbria Pharmaceuticals, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Imbria Pharmaceuticals, Inc. Imbria Pharmaceuticals is focused on advancing novel product candidates to improve or restore cellular energy production, with a mission to translate knowledge of cellular metabolism into medicines that improve patients' lives. The company is engaged in clinical trials and research in cardiometabolic disorders. Industries biotechnology health-care life-science pharmaceutical Nr. of Employees small (1-50) Imbria Pha
BioNJ Announces Lineup for BioPartnering Conference Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview T … armaceuticals BioBridges BOME Pharma CFGI Datasite DLA Piper Fedsprout GenVault Grant Thornton Jersey City Economic Development Corp. Johnson & Johnson J.P. Morgan Marcum Middlesex County Morgan Lewis NJ Commission on Science, Innovation & Technology NJ Israel Commission NJ Economic Development Authority NJ Health Foundation Princeton BioLabs Thermo Fisher Withum "We look forward to welcoming BioNJ's preeminent 2024 BioPartnering Conference to the Liberty Science Cent … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
%PDF-1.7 %���� 1 0 obj >/Metadata 9112 0 R/ViewerPreferences 9113 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 10 0 R 25 0 R 26 0 R 34 0 R 49 0 R 50 0 R 60 0 R 61 0 R 62 0 R 63 0 R 69 0 R 70 0 R 72 0 R 73 0 R 74 0 R 77 0 R 78 0 R] /MediaBox[ 0 0 612 792] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x��\�o�8~��A��b���I 0�8i�{[`��� ���Ը$�������!)Y�H�f��m�Ʀ$�| 3��$��o��?������|�]�~\~�~?�Y�������/����b�Z?�^y��C[.>,7�Yuq9��u|�� �3�VM%�2��,����C�x|tqs|t��T�� �n�<>"p]S���JiR Y� yV … ��$*U�Zz$ҭE��2Q!�����D����Kf>Iν������D��,��ﴛ�BXrԭ0�y��h6��w:�u|$�(8� +Rfp�#���ȼ9�����F��6R�-7�ah��ͫ����*��VY��zz�\� 9N��r�$��~�PiUx �4m��Y�"%l���� �Y# ��� oY�άH��X�y������ͦ���S5;��6����Ep2�&����F��A,Q4��ch����\�Ɗ�����B�X9�o��?.zL��GU��� �h1�fX i~��&�h�Y}����bgI��A,�\:�y�1�\v�1ء �Xp�b� �ʼn,��g�D��乐��Փ���I~U��(�뢈�Q1�H�O)iJ��;[n��T:O+Xzm���]��/�.sz&�tN*B*�J� g ��H =����,E��y%r[#l����ݒ_$��w02�X�[ww�����Ys�ܼ_���rAR�IGͤu�H�%q�#l�d�Q
2026 Cardiovascular Disease: State of the Art - Lahey Clinic - Continuing Education (CE) <strong>Online registration is now closed</strong> so that we may finalize materials and communications for registered attendees.</p><p class="isSelectedEnd">Walk-in registration will be available on-site. Payment may be made by check or credit card at the time of registration.</p><p>Please note that registration fees for walk-in attendees will not be discounted or prorated based on the number of days or sessions attended.</p><p></p><p></p>" /> {1} ##LOC[OK]## {1} … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … ct and clinical use of GLP-1 agonists and other emerging weight-loss therapies. Apply updated treatment recommendations and novel therapies for hypertension and hyperlipidemia. Discuss current and emerging applications of artificial intelligence in cardiovascular medicine and patient care. Registration Physicians: $825.00 Advanced Practice Providers (AP, NP): $650.00 Accreditation Lahey Clinic is accredited by the Accreditation Council for Continuing Medical Educa … of Medicine Boston, MA Faculty Consulting Fee-Livanova (Relationship has ended)|Grant or research support-Livanova (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Cardurian|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Boehringer Ingelheim Pharmaceuticals, Inc.|Consulting Fee-Orizuru|Consulting Fee-SC Pharma (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Member … Relationship has ended) Jonathan Silver, MD Lahey Clinic Burlington, MA Faculty Grant or research support-Abbott (Any division)|Honoraria-Abbott (Any division)|Honoraria-Boston Scientific Corporation|Grant or research support-Boston Scientific Corporation|Grant or research support-Johnson & Johnson|Grant or research support-Medtronic (Any divisio
Participating Companies --> --> --> 3 days in-person. 2 days virtually. January 8–10, 2024 | San Francisco, CA, January 16–17, 2024 | Virtual Menu Home What's On? Agenda Presenting Companies Partnering Opportunities Plan Your Visit Register Now Close Book Now Home What's On? Agenda Presenting Companies Partnering Opportunities Plan Your Visit PARTICIPATING COMPANIES Companies participating at Biotech Showcase 2024 Participating Companies --> Filter Filters Close Search Filters Formats Keynote --> Categories View All Participating Companies Presenting companies Investors Irene Abrams, Animal He … United States Body Vision Medical China BOHE Angel Fund Canada Bold Therapeutics Inc. United States Bonaventure Equity, LLC United States Bond Biosciences, Inc. United States Boom Capital South Korea Boryung Co., Ltd. United States Boston Harbor Angels France Bpifrance Netherlands Brabant Development Agency (BOM) United States Brace Pharma &nbs … cal Angel Network China Chengdu Guanghua Wutong Equity Investment Fund Management Co.,Ltd United States Chiesi Ventures Australia Children's Medical Research Institute Canada Chimeric Therapeutics Limited United States Chimeron Bio United States China Daily USA United States Chrysalis BioTherapeutics, Inc. Ireland Chrysea Limited France Cilcare United States Cincinnati Children's … s United States clock.bio United States Cloudstone Venture Fund, L.P. Japan CLOVERNA, Inc. Australia CMAX Clinical Research United States Coagulant Therapeutics United States Coast Bioventures LLC Canada Cobionix United States Cobro Ventures United States Codon Capital China Codone Biotech United States Coeurative, Inc. United States Cogn … p; United Kingdom DeBere Switzerland Debiopharm Innovation Fund SA United States Decheng Capital United States DeckTherapeutics, Inc. Canada Deep Genomics United States DeepCure United Kingdom DeepMirror United States Deerfield United States Defand Therapeu
Patients - ViCardia Home Clinicians Patients Investors About Home Clinicians Patients Investors About Patients Introduction Heart failure is a progressive syndrome that begins with a chronic condition that often leads to Acute Decompensated Heart Failure, an unstable condition requiring immediate medical treatment. Hospitalization due to ADHF marks a critical stage in the progression of chronic heart failure resulting in an acute event, requiring hospitalization. However, post-discharge mortality reaches 10% within 3 months and 20% within 6 months. Rehospitalization for an acute event rea
ViCardia Therapeutics, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies ViCardia Therapeutics, Inc. ViCardia Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for heart failure involving mitochondrial dysfunction, with a mission to lead in research and treatment targeting mitochondrial dysfunction and AMPK activation to improve patient lifespan and healthspan. Industries biotechnology health-care medical therapeutics Nr. of Employees small (1-50)
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma L … n part, from the decisions of venture capitalists, a key group of investors who fund and incubate many of the young biotechs that later get absorbed by large pharmaceutical companies. Venture firms mostly steered clear of cardiovascular research over the last decade, opting instead to put their money into biotechs focused on cancer, the brain or the immune system. According to data from Silicon Valley Bank, these firms spent a total $534 million on cardiovascular companies in … mp;A possibility is," Norris said. CNS = Central nervous system; NDA = New Drug Application Ned Pagliarulo / BioPharma Dive, data from Cowen & Co. And yet, recent takeouts may be able to drum up more interest in heart drugs, as the right assets can clearly fetch a high price and a significant return for investors. Novartis paid a 24% premium for The Medicines Co. and its experimental drug for high cholesterol. The deal with Bristol Myers, meanwhile, values MyoKardia — its
--> Venture Capital - Sectoral Asset Management - Specialists in global healthcare investment portfolios Venture Capital A differentiated approach to healthcare venture Since 2008, the New Emerging Medical Opportunities (NEMO) family of late-stage venture capital funds has invested in innovative biotech and medtech companies across North America and Europe. In 2023, we launched the Fonds Medtech Ventures (FMV), which focuses on Canadian medtech companies. We use funds and the operational expertise of our entire team to help our companies bring novel therapeutics and medical devices to patients … diagnostic solutions with the potential to be disruptive on a global scale. The Fund finances and plays an active role in executing a development plan that maximises the technologies’ full potential. Sectoral acts as a lead for the majority of initial investments and seeks representation at the board level. New Emerging Medical Opportunities (NEMO) Geography: North America and Europe Sector: Biotechnologies and Medical Technologies Stage: Series B or later The NEMO strategy f
JP2008534601A5 - - Google Patents JP2008534601A5 - - Google Patents Download PDF Info Publication number JP2008534601A5 JP2008534601A5 JP2008504297A JP2008504297A JP2008534601A5 JP 2008534601 A5 JP2008534601 A5 JP 2008534601A5 JP 2008504297 A JP2008504297 A JP 2008504297A JP 2008504297 A JP2008504297 A JP 2008504297A JP 2008534601 A5 JP2008534601 A5 JP 2008534601A5 Authority JP Japan Prior art keywords amino ribofuranosyl deoxy imidazole salt Prior art date 2006-03-28 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and ma … s and makes no representation as to the accuracy of the status listed.) Pending Application number JP2008504297A Other languages English ( en ) Japanese ( ja ) Other versions JP2008534601A ( ja Filing date 2006-03-28 Publication date 2009-05-21 2006-03-28 Application filed filed Critical 2006-03-28 Priority claimed from PCT/US2006/011422 external-priority patent/WO2006105167A2/en 2008-08-28 Publication of JP2008534601A publication Critical patent/JP2008534601A/ja 2009-05-21 P … ための方法、組成物および処方物 Pending JP2008534601A ( ja ) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title US66607105P 2005-03-28 2005-03-28 PCT/US2006/011422 WO2006105167A2 ( en ) 2005-03-28 2006-03-28 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient Related Child Applications (2) Application Number Title Priority Date Filing Date JP2012227810A Division JP2013010795A ( ja ) 2005-03-28 2012-10-15 患者における副作用 … -ETC--item-2587235.html ) 2009-05-21 Family ID=37054068 Family Applications (9) Application Number Title Priority Date Filing Date JP2008504297A Pending JP2008534601A ( ja ) 2005-03-28 2006-03-28 患者における副作用を予防または減少するための方法、組成物および処方物 JP2012227809A Pending JP2013010794A ( ja ) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物 JP2012227810A Pending JP2013010795A ( ja ) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物 JP2014254924A Expired - Lifetime JP6122417B2 ( ja … -28 2025-02-28 患者における副作用を予防または減少するための方法、組成物および処方物 Family Applications After (8) Application Number Title Priority Date Filing Date JP2012227809A Pending JP2013010794A ( ja ) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物 JP2012227810A Pending JP2013010795A ( ja ) 2005-03-28 2012-10-15 患者における副作用を予防または減少するための方法、組成物および処方物 JP2014254924A Exp
Droia Ventures – Investing in Impact – Life Science Investor portal About Droia Portfolio Droia Labs People News Careers Contact About Droia Portfolio Droia Labs People News Careers Contact Investor portal Making a difference Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease. Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress … d investor in small and big biotech, venture capital Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund Luc Verelst Founder & Chairman BA in Biology, University of Virginia PhD in Genetics, University of Wisconsin-Madison Novartis Celgene (Bristol Myers Squibb) Arch Venture Partners Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others George Golumbeski Partner M. Sc. Biomedical Sciences, University of Leuven PhD … Polymers, ULB PhD fellow IWT Recipient VCU RDD Peter R. Byron Graduate Student Award Belgian Brain Tumor Support * Representing KinCon BV Matthias Van Woensel * Partner BA in Biochemistry, Catholic University in Chile PhD in Cell Biology, UCSF Medivation Praxis Biotech Merken Biotech Sebastian Bernales Venture Partner Ph.D. in Molecular Biology from TIFR, Mumbai, India Trained at Yale, NIH and Harvard in RNA metabolism, genetic engineering and immunology mRNA platform lead, … r for Brain & Disease Research In vitro Project Lead - CoBioRes Associate - Fund+ NV CGP certificate - Columbia Business School Lawrence Van Helleputte Senior Associate Evelien Verdrengh Office Manager & Executive Assistant Bioengineer, KU Leuven IBD research group, KU Leuven Labmanager at Flamingo Therapeutics Willem-Jan Wollants Scientist – Droia Labs News 16 March, 2026 Share After Novartis pact, macrocycle shop Unnatural Products gets $45M Series B 24 February, 20
The Galien Foundation Announces 2025 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup" Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse N … honoring innovators in life sciences, today announced the 2025 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup." Winners will be announced during the Prix Galien USA Awards Ceremony on October 30, 2025 , at the American Museum of Natural History in New York City . "As Jury Chair, I am honored to recognize these exceptional nominees who exemplify the transformative power of … inees, and "Best Startup" - 53 nominees. To explore this year's nominees in all award categories, please click here . To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for marketing within the last five years and demonstrate tremendous potential to improve human health. Sales data are not considered by the nominating committee in their award nominee selection, only science and health impact. Best Digital Health Solution (Nominees) Abbott Neur … Hybrid Best Incubators, Accelerators and Equity (Nominees) AVANT BIO AVANT BIO Fund II LP Calibr-Skaggs Institute for Innovative Medicines Calibr-Skaggs Drug Accelerator Cornell University Center for Life Science Ventures Cross-Border Impact Ventures Women's and Children's Health Technology Fund Cube Labs Cube Labs EIT Health EIT Health Accelerator Endless Frontier Labs Endless Frontier Labs MATTER SMILE Health Mayo Clinic Mayo Clinic and Arizona State University Alliance fo … macology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit www.galienfoundation.org . Follow the Foundation on social media: https://www.facebook.com/GalienFoundation/ https://twitter.com/GalienFdn https://www.linkedin.com/company/the-galien-foundation/ &
Carbon Biosciences Announces New Appointments to Board of Directors and Scientific Advisory Board | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Companies - Cure Ventures Skip to content People Companies Approach About Menu Toggle Overview News Community Careers Contact Main Menu People Companies Approach About Menu Toggle Overview News Community Careers Contact Companies with Curative Ambition Breakthrough is Just the Beginning for Our Entrepreneurs Meet a Member of Our Family Tree Dr. Milenko Cicmil, CEO of Tasca Therapeutics As a veteran in the world of drug discovery, the beginnings of my partnership with Cure Ventures and the building of Tasca Therapeutics can be linked back to a single walk in the park with one of the founding pa … hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need. Focus/Therapeutic Area: Oncology Stage/Status: Series A Website: https://www.clasptx.com/ View More Crosslink is engineering cancer medicines that conditionally assemble in the tumor microenvironment. Our technology can be adapted to multiple therapeutic modalities, improving safety and efficacy. Focus/Therapeutic Area: Oncology Stage/S
Home - ViCardia Home Clinicians Patients Investors About Home Clinicians Patients Investors About Addressing the Underlying Cause of Heart Failure Our mission: to be the leader in heart failure research and treatment focused on mitochondrial dysfunction and AMPK activation. Our goal is to improve the healthspan of the acute heart failure patient and to improve their healthy lifespan – living a long and healthy life Heart failure is the cardiovascular epidemic of the 21st century. Worldwide the prevalence of Heart Failure is estimated to exceed 64 million and
2023 Most Fundable Companies | Pepperdine Graziadio Business School Skip to main content Pepperdine | Graziadio Business School Search site x Search Apply Visit Give Menu Academics Admission Student Life Alumni About Newsroom Events Locations Community Popular Links Tuition Library Graziadio at a Glance Graduation Academic Catalog Academic Calendar Faculty Directory Study Abroad Graziadio Blog Recruitment Advisors Back Academics Degrees & Programs Program Comparison Doctor of Business Administration Executive MBA Programs MBA Programs MS Programs Bachelor's Degree Completion Online Master' … Graziadio Newsroom Industry Research Reports Thought Leadership Back Admission Application Information Admission Requirements Admission Deadlines International Students Class Profile Ambassadors Tuition Refer a Student Financial Aid Cost of Attendance How to Apply Forms and Resources Veterans' Benefits Back Student Life Life at Pepperdine Studying in Malibu Spiritual Life University Housing Career Development Student Clubs & Organizations Hallmarks Values-Centered Collab … Most Fundable Companies Events Healthcare Symposium Agenda Past Speakers & Award Recipients Current Speakers Sponsorships George Awards Award Recipients Past Recipients Graduation SEER Symposium Sponsorships Past Speakers MSOD Alumni Conference Most Fundable Companies 2025 Recipients 2024 Recipients 2023 Recipients 2022 Recipients 2021 Recipients 2020 Recipients 2019 Recipients 2018 Recipients Contact 2023 Most Fundable Companies The Winners Congratulations to the 2023 P
SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001. FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00 1. Issuer's Identity CIK (Filer ID Number) Previ … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(5) Section 3(c)(13) Section 3(c)(6) Section 3(c)(14) Sec … more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) X Equity Pooled Investment Fund Interests Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, su … tate/Province/Country ZIP/Postal Code State(s) of Solicitation (select all that apply) Check “All States” or check individual States All States Foreign/non-US 13. Offering and Sales Amounts Total Offering Amount $ 700,000 USD or Indefinite Total Amount Sold $ 700,000 USD Total Remaining to be Sold $ 0 USD or Indefinite Clarification of Response (
Portfolio | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Our Portfolio IPO / Acquired Investments Biotherapeutic Digital Health All abcuro Close Private Newton, MA www.abcuro.com Developing treatments for autoimmune and cancer indications. Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 … ence. Press releases Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Jan 10, 2022 Read More Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform. Mar 25, 2021 Read More Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health Jul 01, 2020 Read More Evidation Health and BARDA Partner on Early Warning System for COVID-19 Jun 04, 2020 Read More Evidation … erited Metabolic Disorders Jul 29, 2014 Read More Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders Jun 30, 2014 Read More Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium Jun 05, 2014 Read More Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients … eutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund Apr 09, 2020 Read More Icosavax Close Acquired Seattle www.icosavax.com Focusing on developing safe and effective vaccines against infectious diseases. Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like parti … res $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support. Feb 25, 2021 Read More Minervax Close Private Copenhagen, Denmark minervax.com Developing a prophylactic vaccine against Group B Streptococcus. Minervax is a clinical stage biotechnology company developing a prophylactic
Michael Kokesh - BIO Investor Forum | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membership Options Bec
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
viCARDIA Therapeutics Raises $3.3M with Strategic Business Support to Combat Heart Failure Epidemic - Norcal SBDC Skip to content Norcal SBDC Northern California Region Services Your Business, Transformed Confidential Advising Recorded Webinars Helpful Resources Food & Hospitality Tech Advising Gov’t Contracting All Services Get Funded SBDC’s Finance Center is where small businesses go to get big money. Get Funded About Us Helping Entrepreneurs Realize Success News & Updates About SBDC Our Region Client Stories SBDC Partners Newsletter We're Local Norcal SBDC has 16 … URL This field is for validation purposes and should be left unchanged. Email * Submit Hosted by: Questions? Call us. Lead Center Office (833) ASK-SBDC Mon — Fri, 9 AM – 5 PM Regional Offices: Butte College SBDC East Bay SBDC Finance Center Lake County SBDC Marin SBDC Mendocino SBDC NorCal VBOC North Coast SBDC Sacramento Valley SBDC San Francisco SBDC San Joaquin SBDC San Mateo SBDC Santa Cruz SBDC Shasta-Cascade SBDC Sierra SBDC Silicon Valley SBDC Solano Napa SBDC Sonoma S … ents located in the Norcal SBDC network coverage area. Funded in part through a grant with the Governor’s Office of Business and Economic Development. Funded in part through a cooperative agreement with the U.S. Small Business Administration. All opinions, conclusions, or recommendations expressed are those of the author(s) and do not necessarily reflect the views of the SBA or Cal Poly Humboldt Sponsored Programs Foundation. Copyright 2026 NorCal SBDC. All Rights Reserved. P
GP-531 by ViCardia Therapeutics for Congestive Heart Failure (Heart Failure): Likelihood of Approval Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insig
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Clinicians - ViCardia Home Clinicians Patients Investors About Home Clinicians Patients Investors About Clinicians ViCardia and GP531 ViCardia is entering Phase 2 with GP531, a potent, long-lasting, infusion therapy that treats mitochondrial dysfunction that leads to chronic heart failure and ultimately to acute decompensated heart failure. Considerable Research Confirms How GP531 Works Milestones Achieved - a lot of work has already been done. Completed to Date 1H 2021 Acadesine 1st Generation ARA R&D An AMPK activator for treatment of ischemic reperfusion injury (IRI
Tenax Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Tenax Therapeutics Tenax Therapeutics is focused on developing therapies for pulmonary hypertension, specifically PH-HFpEF, a debilitating and often fatal disease with no current approved treatments. Their mission is to address the staggering unmet medical need in this area by leveraging clinical insights and innovative drug development strategies. Their lead drug candidate, TNX-103, is an oral formulation of levosimendan, which has a well-established safety
Vicardia Therapeutics inc. San Francisco has appointed me as Chairman of the Board. It has a pioneering drug candidate for Heart Failure. Watch this 5 min video | D A Prasanna | 20 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings … preparing for a public offering in Q 1/20/24. And the proceeds will be used to fund the phase two clinical trial. The phase two is. Demonstrated by this slide. And the FDA has reviewed our protocol and given us the green light to proceed. By Carney believes that it has substantially derisked they phase two clinical trial. The phase two is also a value inflection point. Based on these comparables, we believe by Cardia is potentially a very valuable company. Our management tea